- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Teva launches generic drug for cystic fibrosis patients
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Diplomat becomes distributor of recently approved cancer drug
FLINT, Mich. — Cornerstone Therapeutics has added specialty pharmacy Diplomat to its limited-distribution network for a newly approved treatment for cystic fibrosis, Diplomat said Friday.
Diplomat will distribute Bethkis (tobramycin inhalation solution), which received Food and Drug Administration approval in October for treating chronic bacterial lung infections caused by P. aeruginosa in cystic fibrosis patients.
Cystic fibrosis affects more than 30,000 children and adults, according to the Cystic Fibrosis Foundation, with 1,000 new cases diagnosed each year.
Correction: The original statement from Diplomat incorrectly referred to the name of Cornerstone Therapeutics. This version of the story corrects the original.